|
|
|
|
 |
CliniComp Announces Agreement with Tenet Healthcare Corporation |
| 9/4/2008 @ 7:34 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
CliniComp, Intl., a leading provider of intelligent inpatient electronic medical record and clinical surveillance solutions, today announced an agreement to provide the Essentris Perinatal Solution to Tenet Healthcare Corporation (NYSE:THC), one of the country’s major health systems.
Dallas-based Tenet initially will deploy CliniComp’s Essentris Perinatal in the labor and delivery (L&D) units of seven of its facilities in 12 states, with additional installations planned for 2009 and 2010. Subsequently, additional Tenet facilities will replace current documentation processes in their L&D units with Essentris Perinatal.
A team from Tenet and CliniComp collaborated to configure the perinatal-specific clinical documentation application to best meet the needs of the Tenet facilities. The final, standardized solution was successfully piloted and installed at St. Mary’s Medical Center in West Palm Beach, Fla.
Essentris Perinatal enables hospitals to align documentation with best practice models and provide a methodology to maintain documentation corresponding with changes in regulation. The establishment of uniform documentation will meet standards of care practices from the American College of Obstetricians and Gynecologists, American Academy of Pediatrics and the Association of Women’s Health, Obstetric and Neonatal Nurses. The solution also supports reporting requirements from the Joint Commission.
“We are very excited by Tenet Healthcare’s decision to install the Essentris Perinatal system at seven of its hospitals," said Alan Portela, chief operating officer, CliniComp, Intl. "As a leader in perinatal documentation, our systems have evolved to meet the market’s demand for specialized functionality, combined with enhanced liability protection. We look forward to working with Tenet.”
Built on the award-winning Essentris platform, which provides an intelligent, reliable inpatient electronic medical record and surveillance infrastructure, Essentris Perinatal is uniquely designed to manage clinical workflow across the entire continuum of perinatal care. It provides integrated modules for fetal surveillance, maternal charting and neonatal (level 3) ICU management. The system captures and links all episodes of care, including mother to baby information, into a longitudinal electronic medical record.
About Tenet Healthcare
Tenet Healthcare Corporation, through its subsidiaries, owns and operates acute care hospitals and related health care services. Tenet’s hospitals aim to provide the best possible care to every patient who comes through their doors, with a clear focus on quality and service. Tenet can be found on the World Wide Web at www.tenethealth.com.
About CliniComp
CliniComp is a leading provider of an intelligent, reliable inpatient electronic medical record and surveillance solution suite to leading hospitals and health systems. In its two-decade history, CliniComp has been a pioneer in bridging the gap between the back-office and the bedside by extending existing HIS and ancillary systems to the point of care. The Essentris enterprise solution maximizes IT investment and enforces consistent workflow across all aspects of patient care. Essentris’ use of a single, interdisciplinary, electronic chart enables caregivers to easily access and view of the total clinical experience and provides a new generation of real-time clinical surveillance and analysis tools. The result is a dramatic improvement in quality and safety of patient care, outcomes and clinical decision-making. Essentris is deployed at approximately 70 client sites, including UCLA Healthcare, Baptist Health South Florida and Tenet Healthcare Corporation. CliniComp also has a sizable deployment across the Military Health System, covering more than 45 percent of all Department of Defense beds. For more information, visit www.clinicomp.com or call 800.350.8202. |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, December 4, 2008 |
 |
|
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology Posted 9:48 AM PST
Novio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DVA Vaccines at International DNA Vaccines Conference Posted 7:42 AM PST
Applied Biosystems SOLiD System Named Life Science Innovation of the Year Posted 7:41 AM PST
Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference Posted 7:37 AM PST
Aperio Introduces SecondSlide Digital Slide Sharing Network Posted 7:33 AM PST
|
| |
| Wednesday, December 3, 2008 |
|
|
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7 in Turkey Posted 7:19 PM PST
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study Posted 7:15 PM PST
Biocept Awarded Accreditation by the College of American Pathologists Posted 7:13 PM PST
Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference Posted 7:07 AM PST
|
| |
| Tuesday, December 2, 2008 |
|
|
Quidel Authorizes Additional $25 Million under Stock Repurchase Program Posted 4:02 PM PST
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows Safety and Durable Systemic Clinical Response Posted 8:54 AM PST
Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products Posted 8:51 AM PST
Nirvanix Plays Supporting Role in Ooyala’s Scalable Video Management Platform Posted 8:49 AM PST
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection Posted 8:47 AM PST
Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference Posted 8:25 AM PST
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia Posted 8:24 AM PST
|
| |
| Monday, December 1, 2008 |
|
|
SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis Posted 4:39 PM PST
Quidel to Present at the 20th Annual Piper Jaffray Healthcare Conference Posted 4:27 PM PST
Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal Down Syndrome in First Trimester of Pregnancy Posted 4:26 PM PST
Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio Posted 4:25 PM PST
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference Posted 8:49 AM PST
Applied Nanoscience Announces Successful EPA-FIFRA Registration for NanoFense Formulation Posted 8:46 AM PST
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease Posted 8:45 AM PST
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial Posted 8:39 AM PST
PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial Posted 8:36 AM PST
TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects Posted 8:35 AM PST
DexCom Receives CE Mark Approval for the SEVEN Continuous Glucose Monitoring System European Association for the Study of Diabetes (EASD) meeting Piper Jaffray 20th Annual Health Care Conference Posted 8:29 AM PST
|
| |
| Monday, November 24, 2008 |
|
|
Visage Imaging and Viatronix Sign Comprehensive Marketing Agreement for Virtual Colonoscopy Product Posted 4:27 PM PST
New Noninvasive Prenatal Diagnostic Technology Allows Diagnosis of Inherited Diseases Such as Cystic Fibrosis Caused by Single Gene Mutations Posted 4:23 PM PST
Life Technologies to Present at J.P. Morgan Small/Mid Cap Conference Posted 4:22 PM PST
FDA Extends Review of Somaxon Pharmaceuticals’ New Drug Application for Silenor (Doxepin) by up to Three Months Posted 7:44 AM PST
International Stem Cell Corporation Partners with Absorption Systems to Commercialize Human Stem Cell-Derived Corneal Tissue for Drug Testing Posted 7:40 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
